Ignite Creation Date:
2024-05-05 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00480831
Status:
COMPLETED
Last Update Posted:
2017-05-18
First Post:
2007-05-30
Brief Title:
A Study of PRO95780 in Patients With Previously Untreated Advanced-Stage Non-Small Cell Lung Cancer APM4074g
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Randomized Double-Blind Phase II Trial of Paclitaxel Carboplatin Bevacizumab With or Without PRO95780 in Patients With Previously Untreated Advanced-Stage Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized double-blind Phase II placebo-controlled trial adding on to a background of effective treatment designed to evaluate the efficacy safety and pharmacokinetics of PRO95780 combined with paclitaxel carboplatin bevacizumab therapy in patients with previously untreated Stage IIIB Stage IV or recurrent non-small cell lung cancer NSCLC Approximately 120 patients will be randomized to one of two treatment arms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None